A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase II efficacy/safety studies in children and adolescents with attention deficit hyperactivity disorder (ADHD).